Varenicline Adjunctive Treatment in Schizophrenia

Schizophrenia Clinical Trial

Official title:

Varenicline Adjunctive Treatment in Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00492349
• Other study ID #: HP-00040322
• Status: Completed
• Phase: Phase 4
• Start date: May 2007
• Est. completion date: April 2011

Study information

• Verified date: December 2017
• Source: University of Maryland, Baltimore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The principal aim of the project is to conduct an off-label adjunctive clinical trial evaluating varenicline as a treatment for core neurobiological and clinical deficits in schizophrenia, in addition to evaluating for smoking cessation in schizophrenia patients.

Description:

This is a double-blind, placebo controlled clinical trial in schizophrenia patients. Outcome measures include biomarkers and clinical symptoms and functions, and smoking cessation. Neurobiological and cognitive markers will be measured for short term (2 weeks) and longer-term (8 weeks). Current schizophrenia treatments are mostly ineffective against primary negative symptoms and the cognitive and information processing deficits associated with the disorder. Previous research has identified several neurophysiological deficits in schizophrenia that are enduring, frequently occurring before psychosis, and mark the disease liability. These schizophrenia endophenotypes provide important targets for novel treatment development as they represent the core deficits of the disorder. We hypothesize that sustained nicotinic and dopaminergic modulation by varenicline may ameliorate the core neurobiological deficits seen in schizophrenia patients, which would lead to subsequent clinical improvement. Neurobiological and neurocognitive markers and clinical and functional measures will be obtained to determine 1) short-term effect of varenicline on biomarkers; and 2) longer-term improvement in clinical symptoms, smoking cessation, and functions; and how biomarker changes predict these improvements.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 91
• Est. completion date: April 2011
• Est. primary completion date: May 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Age 18-60

• DSM-IV Diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder

• Clinically stable with no change in antipsychotic medications and increase of daily dose for 4 weeks prior to enrollment

• Sufficient understanding of the study and risks (ESC score 10 or above)

Exclusion Criteria:

• Major medical illness history including, but not limited to, history of heart attack, stroke, TIA (transient ischemic attack)

• History of organic brain disorders that may affect neurophysiological measurements, including seizure disorder, brain tumor, head injury with evidence of significant cognitive deterioration

• DSM-IV diagnosis of substance dependence within 6 months except nicotine and marijuana

• On nicotine replacement therapy (nicotine patch, gum, or nasal spray)

• Uncontrolled blood pressure (persistent systolic above 155 or diastolic above 95)

• EKG of second or third degree atrioventricular (AV) block

• Renal insufficiency with estimated creatinine clearance <40 ml/min

• Women who have positive urine pregnancy tests

• Women who are pregnant, plan to become pregnant, or in breastfeeding

Related Conditions & MeSH terms

• Disease
• Psychotic Disorders
• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorder

Intervention

Drug:
• Varenicline
Varenicline 0.5mg po qd x 7 days then titrated to Varenicline 0.5mg po bid x 7 weeks
• Placebo
Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks

Locations

Country	Name	City	State
United States	Maryland Psychiatric Research Center	Baltimore	Maryland
United States	UMB School of Medicine	Baltimore	Maryland
United States	University of Maryland Medical System	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
University of Maryland, Baltimore	Stanley Medical Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hamilton Depression Rating Scale (Ham-D)	Ham-D Total Score (range 0 to 54, higher score is worse). Definition is fully described in a peer-review journal reported at Arch Gen Psychiatry 2011 Dec;68(12):1195-206.	Week 8
Primary	Memory Saccadic Positional Error, Degrees	A saccade is a quick eye movement. Spatial working memory was assessed by memory saccade. Participants were asked to focus on a target while a peripheral cue was flashed. Participants were signaled to look in the direction of the peripheral cue when the central target was removed, and the positional error was calculated as the distance between the saccadic and peripheral target positions. Definition is fully described in a peer-review journal reported at Arch Gen Psychiatry 2011 Dec;68(12):1195-206.	Week 8
Primary	Predictive Pursuit Gain	Pursuit gain is the averaged artifact-free eye velocity divided by target velocity. Participants are asked to track a target with their eyes. Participants may use a predictive mechanism to perform the tracking. The pursuit gain using the predictive mechanism is calculated. Further definition is fully described in a peer-review journal reported at Arch Gen Psychiatry 2011 Dec;68(12):1195-206.	Week 8
Primary	Maintenance Pursuit Gain	Pursuit gain is the averaged artifact-free eye velocity divided by target velocity. Eye velocity during the regular eye-tracking period (without foveal stabilization) divided by target velocity was used to calculate the maintenance pursuit gain. Further definition is fully described in a peer-review journal reported at Arch Gen Psychiatry 2011 Dec;68(12):1195-206.	Week 8
Primary	Digit Symbol Test	Digit symbol test score (0 to no definite upper range, higher score is better). Definition is fully described in a peer-review journal reported at Arch Gen Psychiatry 2011 Dec;68(12):1195-206.	Week 0, Week 2 and Week 8
Primary	Conner's Continuous Performance Test (CPT) Detectability Score	Conner's CPT Detectability Score (no set normal range, higher is generally better). Definition is fully described in a peer-review journal reported at Arch Gen Psychiatry 2011 Dec;68(12):1195-206.	Week 0, Week 2 and Week 8
Primary	Antisaccade Error Rates	In antisaccade, participants were asked to focus on a central target. When a peripheral cue was presented, participants were asked to look in an equidistant and opposite direction of the peripheral cue. The error rate is calculated as the number of trials in which the participant looked toward the cue, rather than in the opposite direction, divided by the total number of trials. Further definition is fully described in a peer-review journal reported at Arch Gen Psychiatry 2011 Dec;68(12):1195-206.	Week 0, Week 2 and Week 8
Primary	P50	P50 response is a measure of the amplitude of the brain wave in response to a sound, where the positive going amplitude of the brain wave occurring at about 50 milliseconds after the sound. Further definition is fully described in a peer-review journal reported at Arch Gen Psychiatry 2011 Dec;68(12):1195-206.	Week 0, Week 2 and Week 8

External Links

•   Click here for more information about the study: Varenicline Adjunctive Treatment in Schizophrenia